Topline results were announced from a phase 3 trial evaluating Viaskin ® Peanut patch in peanut allergic children aged 4 to 7 years. Viaskin Peanut patch is an epicutaneous immunotherapy that delivers ...
Welcome to the DBV Technologies Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Jonathan Neely. Please go ...
DBV Technologies SA shares soared after the company said its experimental skin patch helped young children with a peanut allergy in a crucial study. The product, called Viaskin, showed it could help ...
The pivotal trial met its primary endpoint. VIASKIN Peanut demonstrated a statistically significant treatment effect, with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. The biopharmaceutical company said Tuesday 46.6% of children who used the patch, named ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback